|Videos|June 27, 2021

Dr. Eure on BPH medications and increased risk of heart failure

Author(s)Urology Times staff

Gregg Eure, MD, FACS, Urology of Virginia, discusses the increased of heart failure associated with medications for the treatment of patients with benign prostatic hyperplasia (BPH). A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

ByHannah Clarke

August 21st 2026

Study shows variability in response to long-term tamsulosin therapy

ByScott R. Bauer, MD, ScM

August 19th 2026

HoLEP learning curve and strategies for successful adoption, with Daniel S. Kellner, MD

ByDaniel S. Kellner, MD

August 17th 2026

Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP

ByNarmina Khanmammadova, MD

August 12th 2026

Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems

ByRavi Munver, MD

July 14th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery